Omeros Corporation (OMER)
| Previous close | 3.8600 |
| Open | 3.8800 |
| Bid | 3.9100 x 800 |
| Ask | 3.9200 x 800 |
| Day's range | 3.6100 - 3.9500 |
| 52-week range | 1.7400 - 7.7500 |
| Volume | |
| Avg. volume | 949,903 |
| Market cap | 246.289M |
| Beta (5Y monthly) | 1.02 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.1200 |
| Earnings date | 08 May 2023 - 12 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 15.25 |
- Business Wire
Omeros Corporation Reports Fourth Quarter and Year-End 2022 Financial Results
SEATTLE, March 13, 2023--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2022, wh
- Business Wire
Omeros Corporation Confirms Absence of Financial Exposure to Silicon Valley Bank
SEATTLE, March 10, 2023--Omeros Corporation (Nasdaq: OMER), in response to investor inquiries, is confirming that it has no banking or other financial relationship with Silicon Valley Bank.
- Business Wire
Omeros Corporation to Announce Fourth Quarter and Year End Financial Results on March 13, 2023
SEATTLE, March 07, 2023--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end financial results for the period ended December 31, 2022, on Monday, March 13, 2023, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.
